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Abstract
Background: Cancer cachexia is a prevalent symptom of head and neck neoplasms. The reduction in skeletal
muscle mass is one of the main characteristics which can lead to poor physical functioning. The purposes of this
pilot randomized controlled trial were to determine the feasibility of progressive resistance training in cachectic
head and neck cancer patients during radiotherapy and to explore possible risks and benefits.
Methods: Twenty cachectic participants with head and neck cancer receiving radiation were randomized to obtain
either a machine supported progressive resistance training (n = 10) or usual care (n = 10). The training took place 3
times weekly for 30 min. Intervention included 3 exercises for major muscle groups with 8–12 repetition maximum
for 3 sets each. Bioelectrical impedance analysis, hand-held dynamometry, Six-Minute Walk Test and standardized
questionnaires for fatigue and quality of life were used for evaluating outcomes at baseline before radiotherapy (t1),
after 7 weeks of radiotherapy (t2) and 8 weeks after the end of radiotherapy (t3).
Results: All participants (n = 20) completed the trial. No serious adverse events occurred. At the initial assessment
the cachectic patients had already lost 7.1 ± 5.2% of their body weight. General fatigue (score 10.7 ± 3.3) and
reduced quality of life (score 71.3 ± 20.6) were prevalent in cachectic head and neck cancer patients even before
radiotherapy. An average improvement of weight loading for leg press (+ 19.0%), chest press (+ 29.8%) and latissimus
pull-down (+ 22.8%) was possible in the intervention group. Participants had at least 13 training sessions. The outcome
measures showed nonsignificant changes at t2 and t3, but a trend for a better course of general fatigue and quality of
life at t2 in the intervention group.
Conclusions: Despite advanced tumor stage and burdensome treatment the intervention adherence is excellent.
Progressive resistance training in cachectic head and neck cancer patients during radiotherapy seems to be safe and
feasible and may have beneficial effects of general fatigue and quality of life.
Trial registration: ClinicalTrials.gov, NCT03524755. Registered 15 May 2018 - Retrospectively registered.
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Background
Head and neck cancer (HNC) is the ninth most common
cause of cancer death [1]. In 2012 an estimated 529,000
new cases of cancer of the oral cavity and pharynx
occurred worldwide. In Germany data describe incidence
estimates of 13,800 and relative 5-year-survival rates be-
tween 48% for men and 61% for women in 2010 [2].
Tobacco use and alcohol consumption are the most
significant risk factors for the development of oral cavity
neoplasms [3]. A strong multiplicative effect for alcohol
interacting with smoking further increases risk [4]. In
addition human papillomavirus infection has a potential
role mainly in the increased incidence for oropharyngeal
cancers [5].
HNC and its medical treatments can lead to a complex
interacting range of adverse effects which includes fatigue
[6], altered body image [7], modified nourishment [8], psy-
chosocial distress [9], shoulder dysfunction [10], trismus
[11], dysphagia [12], xerostomia [13], mucositis [14], cach-
exia [15, 16], all resulting in reduced quality of life [17].
Modern radiotherapy techniques can reduce acute and
chronic side effects. Intensity modulation [18, 19] and
image guided [20] radiotherapy allow improved dose dis-
tribution thus sparing critical organs and improving
quality of life [21, 22].
Considering the above mentioned debilitating symp-
toms, rehabilitation for HNC patients is warranted and
potentially beneficial after medical treatment. In recent
years it has been shown that physical exercises after and
even during treatment relieve many of the side effects
experienced by patients with various neoplasms [23–25].
Cancer cachexia and its key feature of weight loss do
not develop to the same extent in every cancer entity.
One of the high-risk populations developing cachexia is
HNC patients [26, 27]. A generalized inflammatory state
with high interleukin-6 levels is seen as a critical factor
for muscle wasting [28, 29]. Loss of muscle mass leads
to asthenia which is responsible for poor physical func-
tioning [30].
The primary objectives of this pilot feasibility random-
ized controlled trial (RCT) were to determine the prac-
ticability of recruitment and the feasibility of progressive
resistance training (PRT) during radiotherapy (RT) for
cachectic HNC patients. Secondary objectives were to
gather preliminary results for safety and responsiveness
of the training.
Methods
Trial design
This study is a pilot, 2-arm, RCT. Between June 2013
and January 2015 a total of 20 patients at the university
hospital Munich, Großhadern were randomly assigned
to receive PRT (intervention group) or usual care (con-
trol group) during RT. Ethical clearance was obtained
from institutional ethics committee (Project-Nr. 531–12)
and written informed consent obtained from all partici-
pants before initiating study activities. Participants with
a cancer diagnosis of the lung, pancreas, esophagus,
head and neck, colon, rectum or anus were subsequently
reviewed for inclusion and exclusion criteria. Study in-
clusion criteria were: (1) planned inpatient or outpatient
RT, (2) ≥ 18 years of age, (3) diagnosed state of cachexia
(weight loss greater than 5% over the past 6 months) or
pre-cachexia (unintentional weight loss of 5% or less of
usual body weight during the last 6 months). Patients
with (1) metastatic disease, (2) severe neurological prob-
lems or other contraindications for the PRT were ex-
cluded. The project coordinator screened potential
participants for eligibility via MOSAIQ®-Software (Radi-
ation Oncology Information System). This software
manages the aspects of the radiation oncology program
and collects all information of the patients and makes
them accessible. Study information sheets were sent to
patients in the form of invitation letters. Participants
who met the diagnosed tumor localization were met at
the time of computer tomography-planning to explain the
study, screen again for eligibility, and obtain informed
consent. Registered participants were planned for baseline
assessment. Participants were allocated at random to the
control or exercise group via blocked randomization in
sealed envelopes.
Baseline data for all participants were ascertained via
medical records and patient interview. This included
demographic information, UICC-status (Union inter-
nationale contre le cancer, tumor staging system), co-
morbidities and the results of blood samples. One study
coordinator completed all assessments to enhance pa-
tient compliance. Body weight loss percentage was cal-
culated via the individuals’ body weight 6 months before
(in retrospect) and the current body weight. Participants
completed two questionnaires: The Multidimensional
Fatigue Inventory (MFI) [31] which consists of 20 items
that measure subgroups (general, physical and mental fa-
tigue as well as reduced motivation and reduced activity)
of fatigue with a 5-point Likert scale and the Functional
Assessment of Anorexia/Cachexia Therapy (FAACT)
questionnaire [32, 33] which registers well-being for
physical, social/family, emotional and functional aspects
of quality of life and additional concerns in cachexia
with 5-point Likert scale for 39 items. To measure phys-
ical performance the Six-Minute Walk Test (6MWT)
[34] was applied. This assessment instrument includes
walking distance as well as heart rate, pulse oximetry
(Contec Medical Systems CO., Ltd., Model: CMS50E),
fatigue (with a rating of perceived exertion (RPE) from 0
to 10) and dyspnea (RPE 0–10) before and after the test.
To document changes in muscle force, strength of the
functional muscle group for elbow flexion in supine
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position as well as of knee extension in sitting position
(in each case right and left) was tested via hand-held dy-
namometry (Mecmesin Ltd., Broadbridge Heath, West
Sussex, RH12 3IR, UK) for isometric maximal muscle
strength [35]. Bioelectrical impedance analysis (BIA;
AKERN SRL, BIA 101 New Edition) was executed to as-
sess the adaption in body composition [36]. Patients
were lying supine on a therapy table. The measurements
took place at the right side of the body with the
tetrapolar-technique of 4 standard electrodes on the sur-
face of the hand and the foot. Constant frequency of
50 kHz and 400 μA constant current in electrical resist-
ance of the body were used to measure resistance and
reactance. The above mentioned assessments were car-
ried out at baseline (t1), after 7 weeks of radiotherapy
(t2) and 8 weeks after radiotherapy (t3).
Before each training session the current condition of
the patient was accurately gathered. This included com-
munication with the responsible nurse and/or physician
about the ongoing state, including the results of the lat-
est investigations such as blood pressure, temperature
and laboratory investigations. As a last safety action the
patient was asked if he felt able to carry out the training.
Heart rate during training was monitored by a chest
strap that sends the current heart rate by a radio signal
to a wristwatch. It was payed attention that the partici-
pant’s heart rate never exceeded the maximum heart rate
measured during the 6MWT and that the heart rate be-
came slower in the breaks during the sets and the
changes to another exercise machine. After the training
each inpatient was personally carried back to the ward
and asked for any complaints. Furthermore, the respon-
sible nurse and/or physician were informed about the
patients return to the ward and any noticeable situations
during the training.
The exercise intervention was undertaken in the hos-
pitals department of physical and rehabilitation medicine
and based on standardized but individualized training
protocols. All exercises were carried out within the indi-
viduals given limb range of motion and in a dynamic
way without defined execution time for the concentric
and eccentric phase. Goal of the very first training was
to determine the training load set for hypertrophic adap-
tion. Because of the vulnerable patient group a submaxi-
mal step by step approach within 3 sets and 8–12
repetitions was chosen. The first two sets acted as both
muscular and movement adaption. The last set served as
submaximal one-repetition maximum estimation. The
evaluation of the training prescription was done in
real-time by a supervising physiotherapist.
The training protocol consisted of a warm up period
for 5 min on a bicycle ergometer or an upper body cycle
with individual selectable wattage. A leg press, a latissi-
mus pull-down and a chest press (Kaphingst) formed the
three equipment supported core exercises. All exercises
were performed with 8–12 repetitions and 3 sets. After
each set and during the changes to another exercise ma-
chine a break of maximum 60 s was assured. After each
machine the patients rated their perceived exertion from
0 to 10. The weight loading was increased at the next
workout if RPE < 7. For the two upper limbs exercise a
progression of 2.5 kg weight loading and for the lower
limbs exercise a progression of 5.0 kg weight loading
was implemented. The exercises were supervised all the
time for performance and safety reasons by physiothera-
pists experienced in oncology rehabilitation and certified
in medical training therapy.
For exercise participants with concomitant chemother-
apy to their RT protocol timing for the training inter-
vention was organized e.g. between the changes of 24 h
constant-rate infusion. In the rare cases where this was
not possible the exercise intervention was adjusted in
order to protect the peripheral venous catheter in the
Vena mediana cubiti by limiting an exercise in the range
of motion or by replacing the two upper body machine
supported exercises by: low pulley seated bench cable
crossover and low pulley lateral extensions because of
the almost static elbow angulation.
The control group received usual care. This could
include inpatient physiotherapy if prescribed by the ward
physician. Muscle strengthening techniques were not
part of the usual care.
Statistical analyses
Descriptive statistics were calculated to check for data
normality. Normality was tested using Kolmogorov-
Smirnov test. Single variables were compared using
Student’s t-test and dichotomous outcomes were ana-
lyzed using a Chi-squared test or Fisher’s exact test as
appropriate. Between group analysis was done using in-
dependent t-test or Mann-Whitney test. Statistical sig-
nificance was set as p < .05. The statistic package IBM
SPSS 23 was used for these analyses.
Sample size
Physical outcomes have been tested following exercise
interventions in cancer studies. The outcome of physical
function was analyzed with meta-analytic procedures
and the overall weighted mean effect size for two-group
comparisons was 0.52 [37]. This effect size calculated
with an α-error probability of 0.05 and a power of 0.8
for a two-sided t-test resulted in a required sample size
of 120 participants. For the control and intervention
group 60 participants each.
Results
On review of the recruitment process in July 2014 it was
noted that there were only HNC patients included (one
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patient with esophageal cancer). Afterwards solely HNC
patients were screened for inclusion criteria to generate
a homogenous analysis.
Patient recruitment (Fig. 1)
Between June 2013 and January 2015 100 eligible cancer
patients scheduled for RT treatment were subsequently
screened. 20 patients were included giving a recruitment
rate of 20%. 80 patients were excluded for following rea-
sons: metastases (n = 20), second cancer diagnosis and/
or relapse (n = 18), no exercise therapy possible due to
other comorbidities (n = 8), no interest (n = 16), no time
(n = 4), RT at non-study site (n = 3) and other reasons
(n = 11). All included patients were randomized into
intervention and control groups before beginning RT.
The completion rate was 100%.
Feasibility outcomes
The 10 participants from the training group achieved a
total of 168 training sessions, with a mean of 16.8 train-
ing sessions (range 13–25) during the course of RT. A
total of 84 h of training could be accomplished with
30 min for each session. This is a mean of 8.4 h of train-
ing for each exercising patient. A mean of 32 days of RT
(range 25–33) results in 2.7 training sessions of the
planned 3 sessions per week (range 1.7–3.8). Mean time
between hospital admission and the first training session
was 1 working day (range 0–3). Mean time between the
last training session and the last RT was 3 working days
(range 13–0). Explanations for not completing all
planned training sessions included pain due to severe
mucositis (4 patients). Change from in- to outpatient
status during RT led to reduced training time slots be-
cause participants had to organize the time for training
considering RT time (4 patients). Three participants re-
ported paused progression in the exercise of a latissimus
pull-down due to abdominal tension following recently
placed percutaneous endoscopic gastrostomy (PEG).
None of the participants reported muscle strains to the
physiotherapist. No infections of peripheral venous cath-
eter, no chemotherapy extravasation and no other adverse
events during or after the training were observed.
Inpatient physiotherapy was prescribed in 3 participants
of the control group. Chest physiotherapy to facilitate
expectoration and movement therapy for the shoulder
girdle after neck dissection were contents of the therapy ses-
sions. A total of 17 therapy sessions with 15–35 min were
carried out.
Fig. 1 Participant flow chart
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Clinical characteristics
The study population (n = 20) consists of upper aerodi-
gestive tract neoplasms of which 85% (n = 9 intervention,
n = 8 control) are head and neck squamous cell carcin-
oma (HNSCC). Whereas the remaining 15% are patients
with tumors of the esophagus (n = 1 intervention) or the
salivary gland (n = 2 control).
Table 1 shows the baseline characteristics of the pa-
tients. Both of the groups were comparable at baseline
with regard to age, sex, cancer stage, alcohol and smok-
ing in the medical history, medical treatment, carried
out neck dissection and PEG. Of the 20 patients 15 were
men and 11 had a history of either smoking and/or alco-
hol abuse. 35% received RT as single medical treatment.
All patients received fractionated radiotherapy with 60–
70 Gy (five fractions/week). Thirteen patients received
concurrent chemotherapy, most of them cisplatin
20 mg/m2 and 5-fluoruracil 600 mg/m2 body surface
area on day 1–5 and repeated as of day 29. Neck dissec-
tion and percutaneous endoscopic gastrostomy has been
performed in 11 patients each.
The comparison of baseline values for blood sample
data (C-reactive protein p = 0.922, hemoglobin p = 0.710
and interleukin-6 p = 0.620) and bodyweight (p = 0.094)
or weight loss (p = 0.274) was similar between both
groups. At the time of giving consent to the study
patients had lost at an average 7.1 ± 5.2% of their body
weight (72.1 ± 12.7 kg) as compared to 6 months before.
C-reactive protein (standard value ≤0.5 mg/dl) was only
slightly increased (1.0 ± 1.5 mg/dl) and hemoglobin
(standard value 13.5–17.5 g/dl) was at the lower limit
(13.4 ± 1.3 g/dl). Elevated interleukin-6 levels (12.0 ±
18.2 pg/ml, standard value ≤5.9 pg/ml, n = 18) were
also shown.
All participants (n = 20) were assessed for functional
capacity with the 6MWT. It shows a mean of 475 ± 101 m
(intervention group 500 ± 77 m, control group 450 ±
119 m, between group analyses p = 0.284). Hand-held
dynamometry for testing maximal isometric strength
demonstrated for knee extension of right lower extremity
30.2 ± 11.9 kp, left lower extremity 30.0 ± 11.9 kp (be-
tween group comparison p = 0.254 respectively p = 0.077).
Isometric testing of the upper extremity via flexion of the
elbow showed for the right side a mean of 18.8 ± 6.0 kp
and left 19.0 ± 5.8 kp (between group comparison p =
0.171 respectively p = 0.433).
The results of the questionnaires for fatigue (Multidi-
mensional Fatigue Inventory) and quality of life in an-
orexia/cachexia (Functional Assessment of Anorexia/
Cachexia Therapy) are presented in Table 2. These show
that both groups were balanced at baseline. Fatigue sub-
scale scores range from 8.0–11.5 and the FACT-G score
is 77.9 ± 15.2, demonstrating a moderate symptom oc-
currence before medical treatment.
We found comparable baseline values for muscle
(p = 0.917) and fat (p = 0.279) mass between the groups.
A mean of 41.8 ± 7.7% (29–59) muscle mass and 19.9 ±
8.3% (3–35) fat mass was shown (n = 20)
Training effects (Table 3)
The increase in general (p = 0.879), physical (p = 0.478)
and mental (p = 0.696) fatigue is not significantly different
between t1 and t3 comparing intervention and control
group. Similarly, the reduced activity increased in both
groups (control 8%, intervention 11%) to a non-signifi-
cantly extent (p = 0.700). In the reduced motivation di-
mension, the intervention group showed a decrease of 7%,
Table 1 Clinical characteristics
Variable All
(n = 20)
Intervention (n = 10) Control
(n = 10)
P value
Age (years) 60.9 ± 11.3 (27–82) 60.2 ± 4.7 (50–66) 61.5 ± 15.7 (27–82) 0.807
Sex 0.303b
Men 15 (75%) 9 (90%) 6 (60%)
Women 5 (25%) 1 (10%) 4 (40%)
Cancer stagea 0.420
Stadium I/II 6 (30%) 3 (30%) 3 (30%)
Stadium III/IV (M0) 14 (70%) 7 (70%) 7 (70%)
Alcohol abuse, yes 5 (25%) 3 (30%) 2 (20%) 1.000b
Smoking, yes 6 (30%) 3 (30%) 3 (30%) 1.000b
Chemoradiation, yes 13 (65%) 8 (80%) 5 (50%) 0.350
Neck dissection, yes 11 (55%) 5 (50%) 6 (60%) 1.000
Feeding tube, yes 11 (55%) 7 (70%) 4 (40%) 0.370b
aUICC Classification
bFisher’s exact test
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while the control group indicated an increase of 14% be-
tween t1 and t3 (p = 0.437).
Comparing the decrease in quality of life in the control
and intervention group is non-significant (p = 0.891).
The relative decrease between t1 and t3 was 7% in the
intervention group and 19% in the control group. In the
period between t1 and t2 the quality of life of the control
group decreased by 27% and in the intervention group
by 18%.
The intervention group shows a 30% loss of fat mass,
the control group decreased 20% of fat mass in the obser-
vation period. In the t2-t3 interval, the untreated group in-
creased its fat mass by 2% and the intervention group
decreased 16%. While the lean mass in the intervention
group increased by 1% during the observation period, it
decreased by 3% in the control group (p = 0.267).
Training progression
All of the 10 participants had a minimum of 13 training
sessions. Figure 2 displays the mean course of the training
regarding weight loading (in kg) for the 3 equipment sup-
ported exercises: leg press, chest press and latissimus
pull-down in the first 13 sessions. Increases in strength can
be shown for each of the equipment supported exercises.
Especially during the first 5 sessions of the training it was
possible to increase the load substantially (see Fig. 2). After-
wards the progression in loading tended to level off. During
the whole course of 13 training sessions there was an aver-
age increase of 19.0% of weight loading for the leg press;
starting from 63.2 kg in the first session and 75.2 kg in the
last. Weight loading for the chest press began at 31.2 kg to
40.5 kg at last; equivalent to an improvement of 29.8%.
Maximum weight loading for the latissimus pull-down was
in the fifth training session (starting with 28.5 kg and end-
ing 35.0 kg; 22.8% weight loading progression).
Discussion
The primary intention of this prospective trial was to
determine the feasibility of individually tailored PRT in
cachectic patients diagnosed with HNC. The main find-
ing of the present study is that even in cachectic patients
with HNC receiving RT a PRT seems to be safe and well
tolerated. None of the participants reported muscle
strains. No infections of the peripheral venous catheter,
chemotherapy extravasation or other adverse events
were reported during or after the training. Additionally,
it was possible to increase the training loads within the
first 5 sessions and maintain them throughout the med-
ical treatment.
When considering physical strength as an outcome par-
ameter it is important to be able to quantify muscle
strength. Strength measurement in this trail needed to be
easy to apply, mobile and inexpensive. A hand-held dyna-
mometric device was therefore used to measure maximal
isometric muscle strength. This pilot study was able to
show 294 ± 117.7 Newton for knee extension at baseline.
Although Knols et al. [38] found similar data (278 ± 93.6
Newton) their sample was more than 10 years younger
(49.45 ± 14.85 vs. 60.9 ± 11.3) and in various types and
stages of cancer chemotherapy treatment. The compari-
son of strength values measured via a hand-held dyna-
mometry are not generalizable as can be seen by the fact
that reliability is significantly influenced by the strength of
the tester [39]. Therefore, the measurements should al-
ways be carried out by the same tester within a study (as it
was done in our trial). The 6MWT is a valid measurement
for physical performance in cancer patients. This was also
demonstrated in this study with a mean distance of 475 ±
101 m achieved. When compared to the walking distance
(652 m) in healthy population based samples [40] the
discrepancy could be explained as a result of the decreased
Table 2 Baseline data for fatigue and quality of life in anorexia/cachexia
Variable All
(n = 20)
Intervention (n = 10) Control
(n = 10)
P value
Fatigue
MFI general fatigue (4–20) 10.7 ± 3.3
(5–16)
11.3 ± 3.7
(5–16)
10.1 ± 2.9
(6–14)
0.393
MFI physical fatigue (4–20) 11.0 ± 4.1
(4–20)
12.0 ± 5.0
(4–20)
10.0 ± 2.9
(6–14)
0.393
MFI reduced activity (4–20) 11.5 ± 4.0
(4–20)
11.5 ± 5.0
(4–20)
11.4 ± 2.7
(6–15)
0.912
MFI reduced motivation (4–20) 8.8 ± 3.9
(4–16)
8.6 ± 4.2
(4–16)
9.0 ± 3.9
(5–16)
0.853
MFI mental fatigue (4–20) 8.0 ± 4.1
(4–20)
7.6 ± 4.9
(4–20)
8.3 ± 3.4
(4–13)
0.436
Quality of life in anorexia/cachexia
FACT-G total score (0–108) 77.9 ± 15.2a
(49–104)
80.1 ± 11.2b
(61–96)
75.7 ± 18.8b
(49–104)
0.730
an = 18, bn = 9 (three patients had a overall item response rate smaller than 80%)
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physical function caused by cachexia. Cachexia not only re-
duces physical activity which leads to noteworthy changes
in performance status. It also directly impacts on quality of
life which is a complex outcome measure in cancer patient
trials. Both cachectic NSCLC and HNC patients seem to
have a similar reduction in quality of life related to an-
orexia/cachexia. A FAACT score of 111 ± 17 was reported
[41] for 26 patients with anorexia-cachexia syndrome in an
outpatient cancer care situation. Among our patients a
FAACT sore of 112 ± 23 seems to be comparable. This is
surprising considering that HNC patients regularly have to
cope with tracheostoma or feeding tubes that are required
to bypass tumor-related complications. This often leads to
changes in eating habits which also can have an effect to
the adaption and change of muscles when they are used.
Especially resistance training provokes an increase in the
cross-sectional area of the muscle fiber types, referred to as
muscle hypertrophy, which is able to gain muscle weight if
factors such as age, sex, nutrition and training status have a
positive basis in an individual. Strength gains during the
early phases of resistance training are a common adaption
of the neuro-muscular system [34, 35]. It could be shown
that during the first five training sessions patients were able
to progressively increase loading compared to the following
sessions. Consequently the neuro-muscular-system was
able to process more loading in this early phase of
training. The training resistance could also be in-
creased more easily at the beginning because no side
effects such as painful mucositis had yet occurred.
The performance stagnation in the further course of
the training could be explained by the fear of pushing
oneself additionally or to the begin of adverse side
effects to the medical therapy.
BIA serves to determine the body composition. Per-
centage body fat was measured with BIA in our trial at
baseline. Sun et al..... [42] measured BIA in 591 healthy
volunteers with a mean age of 42.15 ± 10.27 (19–60) and
found a body fat mass of 32.85 ± 8.00 (10.6–58.3) per-
cent. In Isenring et al’s research HNC patients were ran-
domized before RT in a nutrition intervention (NI)
group or a usual care (UC) group [43]. Both groups in
Isenring et al’s research were comparable at baseline
with respect to fat mass in kg (19.4 ± 4.8 vs 20.5 ± 9.7; p
= 0.640). A calculated mean of 25.1% fat mass in the NI
group and 26.7% in the UC group is comparable to our
analyzed fat mass of 19.9 ± 8.3%. The lower fat mass in
this study could be explained with the cachectic state of
our patients. Research into body composition status with
respect to skeletal muscle mass in advanced esophageal
cancer patients undertaken by Ida et al. 30 patients
underwent BIA before neoadjuvant chemotherapy [44].
They found a mean muscle mass of 24.9 ± 0.8 kg with a
mean body weight of 59.1 ± 1.7 kg which corresponds to
42.1% muscle mass proportion. With 37% Takekiyo et al.
[45] found approximately equal values for muscle mass
at baseline. In their analysis eighty-six patients under-
went BIA before hematopoietic stem cell transplant-
ation. When compared to our results of 41.8 ± 7.7%
muscle mass in an already cachectic patient sample seems
to be quite a lot. Cancer cachexia is however a heteroge-
neous phenomenon which can vary through the time
spectrum (pre-cachexia, cachexia, and refractory cach-
exia), tumor type, site and mass. Metabolic change as well
as reduced food intake, co-morbidity, pre-existing sarco-
penia, cancer therapy and genetic predisposition can play
a role in cancer cachexia [46].
Table 3 Training effects of fatigue dimensions, quality of life and
fat and lean mass at test intervals t1, t2 and t3
Variable Intervention
n = 10
Control
n = 10
P Value
(t1-t3)
Fatigue (4–20)
General Fatigue pre 11.3 ± 3.7 10.1 ± 2.9 0.879
General Fatigue post 12.3 ± 5.3 14.1 ± 3.5
General Fatigue follow-up 11.8 ± 4.3 11.9 ± 4.6
Physical Fatigue pre 12.0 ± 5.0 10.0 ± 2.9 0.478
Physical Fatigue post 13.5 ± 4.5 13.8 ± 2.8
Physical Fatigue follow-up 13.3 ± 5.0 11.8 ± 5.1
Mental Fatigue pre 7.6 ± 4,9 8.3 ± 3.4 0.696
Mental Fatigue post 9.6 ± 4.4 9.7 ± 4.0
Mental Fatigue follow-up 8.3 ± 2.3 9.2 ± 2.3
Reduced Activity pre 11.5 ± 5.0 11.4 ± 2.7 0.700
Reduced Activity post 13.1 ± 4.8 14.8 ± 2.8
Reduced Activity follow-up 12.4 ± 4.4 12.6 ± 4.2
Reduced Motivation pre 8.6 ± 4.2 9.0 ± 3.9 0.437
Reduced Motivation post 9.2 ± 4.1 9.9 ± 2.2
Reduced Motivation follow-up 8.0 ± 2.5 10.3 ± 4.8
Quality of life in anorexia/cachexia (0–104)
Quality of Life pre 80.1 ± 11.2 75.7 ± 18.8 0.891
Quality of Life post 56.5 ± 18.4 53.4 ± 19.8
Quality of Life follow-up 64.4 ± 18,4 59.5 ± 26.5
Bioelectrical Impedance analysis (kg)
Fat mass pre 14.7 ± 8.6 16.4 ± 7.0 0.545
Fat mass post 12.1 ± 7.0 12.9 ± 6.2
Fat mass follow-up 10.2 ± 6.6 13.2 ± 5.3
Lean mass pre 58.6 ± 4.9 54.4 ± 12.5 0.267
Lean mass post 57.8 ± 8.9 53.5 ± 11.9
Lean mass follow-up 59.1 ± 7.1 52.7 ± 12.1
Variables: Fatigue Multidimensional Fatigue Inventory (possible scoring 4–20),
Quality of life in anorexia/cachexia Functional Assessment of Anorexia/Cachexia
Therapy FAACT questionnaire (possible scoring 0–104), Bioelectrical Impedance
analysis Body composition measurement (in kilogram); pre (t1): before
radiotherapy, post (t2): after 7 weeks of radiotherapy and follow-up (t3):
8 weeks after radiotherapy represent the time at which the outcome was
assessed. Analysis of variance for repeated measurements with the two factors
Time and Group, p < 0.05
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Training effects
Although the results of the MFI did not show any signifi-
cant differences between groups over the study period, it
should be noted that in 4 out of 5 subcategories, the control
group had a higher average percentage increase in fatigue
scores over the interval t1 to t2. The main difference was
found in the dimension general fatigue. In this dimension
the fatigue score in the intervention group worsened by 9%,
whereas the control group experienced a 40% worsening.
This is in line with a Cochrane review that found a signifi-
cant beneficial effect of tumor related fatigue in patients
who performed aerobic exercise and positive, although
nonsignificant, trends for resistance training and other
forms of exercise therapy [47].
In the t1-t2 period the questionnaire FAACT showed a
notable result for the quality of life of cachectic tumor
patients. Here it is indicated that the decrease in quality
of life by 18%, compared to the control group with 27%,
the intervention group had less loss of quality of life over
the period of medical therapy. Cancer patients often
have many mental and physical side effects as a result of
their cancer or treatment. Some studies have suggested
that physical exercises may be helpful in reducing nega-
tive outcomes and improving the quality of life of cancer
patients during their treatment [48].
The via bioelectrical impedance analysis measured lean
mass essentially represents the mass of the muscles, the
organs, the skeletal system and the central nervous sys-
tem. The lean mass is calculated on the basis of body
water (total body water / 0.73 = lean mass). A relatively
constant hydrogenation of 73% is assumed. This could
also basically mean that the courses of the lean mass and
the total body water are similar. The control group loses
3% (intervention + 1%) lean mass over the entire study
period. However, as the subjects are tumor patients who
suffer from oral fluid and food intake limitations, the re-
sults are arguable. Fat mass is calculated from the weight
difference of lean mass and body weight. Both groups lost
a noteworthy proportion of their fat mass throughout the
study period. By contrast, the decrease in muscle mass
only affected the period from t1 to t2. There, both groups
equally relieved muscle mass. During the same period, the
intervention group lost 18% and the control group 21% of
their fat mass. This result is consistent with the statement
that in tumor patients fat is degraded to a greater degree
than muscle mass [49]. This result allows important con-
clusions: Firstly, a nutritional intervention with a fatty
component should be incorporated as soon as possible
and in the long term in order to reduce the early and pref-
erential breakdown of fat mass. On the other hand, the
musculature necessary for the functioning of patients in
their daily environment appears to be a non-primary
source of supply for the maintenance of cachexia.
In our sample of cachectic HNC patients the selected
assessments for the measurement of physical perform-
ance, quality of life and body composition could be im-
plemented without difficulty.
The present pilot study has certain limitations. The
small sample size and non-blinding of assessors and
therapists are major limitations which reflect lack of
time and budget in pilot studies. Especially in physical
activity studies selection bias is ubiquitous and generates
an inevitable risk for data extrapolation. Appropriately
powered analyses were not sought due to the pilot char-
acter of this study. However, randomization, the pres-
ence of a control group and an approach to characterize
cachectic body components as an outcome measure for
resistance training are major strengths of this study.
Fig. 2 Weight loading progression during the first 13 training sessions for the equipment supported exercises
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Conclusion
In this pilot RCT a new therapy focus on the high-risk
patient group of cachectic HNC patients during RT has
been established. Progressive resistance training during
RT for cachectic HNC patients is feasible. In our sample
of patients, it was well tolerated and safe, but due to the
small sample size we may have missed less frequent ad-
verse events. In the early phase of training patients could
progressively manage more resistance. This suggests that
cachectic HNC patients might benefit from PRT in the
early phase of RT. No significant benefits in fatigue and
QOL were found, but the slightly better outcomes for
general fatigue and QOL in the intervention group and
the feasibility results can be used to design a future de-
finitive clinical trial.
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